A study linked high expression of the protein desmoglein-2 (DSG2) to lower survival in people with myeloma. Data suggest that high DSG2 expression is…

A combination treatment using two Johnson & Johnson immunotherapies outperformed standard care regimens in reducing the risk of disease progression and death among people…

The experimental anticancer therapy CR-001 was generally well tolerated in a first-in-human clinical trial that tested several doses in 11 people with acute myeloid leukemia…